NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET® -AML test for early detection of acute myeloid leukemia (AML) in patients with myelodysplastic syndrome (MDS).
The European Medicines Agency (EMA) is advising marketing authorisation holders to submit type IA and type IAIN variations for 2021 no later than Tuesday 30th November, 2021. This will enable EMA to acknowledge the validity of the submissions before the Agency's closure between 23th December, 2021 and 3 January 2022 and within the 30-day timeframe set out in Article 14 of Commission Regulation (EC) No 1234/2008